ID

15234

Beskrivning

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany

Länk

https://clinicaltrials.gov/ct2/show/NCT02419378

Nyckelord

Versioner (4)
  1. 2015-08-13 2015-08-13 - Martin Dugas
  2. 2016-05-23 2016-05-23 -
  3. 2016-05-24 2016-05-24 -
  4. 2016-05-28 2016-05-28 -
Uppladdad den

23 maj 2016

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0 Legacy
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

Engelsk

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

1 Formulär  
Criteria for Treatment deferral
Beskrivning

Criteria for Treatment deferral

Alias
UMLS CUI-1
C0087111
UMLS CUI-2
C0205421
Patient ID (derived)
Beskrivning

Patient ID (derived)

Datatyp

text

Alias
UMLS CUI [1]
C2348585
Visit Info
Beskrivning

Visit Info

Datatyp

text

Alias
UMLS CUI [1]
C0545082
Recent relapse of MS
Beskrivning

Recent relapse of MS

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0856120
Recent vaccination ≤ 6 weeks
Beskrivning

Recent vaccination ≤ 6 weeks

Datatyp

boolean

Alias
UMLS CUI [1]
C0042196
Malignancy, except basal skin cell carcinoma
Beskrivning

Malignancy, except basal skin cell carcinoma

Datatyp

boolean

Alias
UMLS CUI [1]
C0006826
Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)
Beskrivning

Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)

Datatyp

boolean

Alias
UMLS CUI [1]
C3251812
Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.
Beskrivning

Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety
Beskrivning

Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety

Datatyp

boolean

Alias
UMLS CUI [1]
C0442893
Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP
Beskrivning

Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP

Datatyp

boolean

Alias
UMLS CUI [1]
C0040034
CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed
Beskrivning

CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed

Datatyp

boolean

Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed
Beskrivning

Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed

Datatyp

boolean

Alias
UMLS CUI [1]
C0853697
Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab
Beskrivning

Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab

Datatyp

boolean

Alias
UMLS CUI [1]
C3843746
Treatment with immunosuppressive or antineoplastic drugs
Beskrivning

Treatment with immunosuppressive or antineoplastic drugs

Datatyp

text

Alias
UMLS CUI [1]
C0021081
Is the patient free of the above listed deferral criteria?
Beskrivning

Is the patient free of the above listed deferral criteria?

Datatyp

boolean

Alias
UMLS CUI [1]
C0205421
Comment Treatment deferral
Beskrivning

Comment Treatment deferral

Datatyp

text

Alias
UMLS CUI [1,1]
C0205421
UMLS CUI [1,2]
C0947611
Tillbaka till toppen

Similar models

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Criteria for Treatment deferral
C0087111 (UMLS CUI-1)
C0205421 (UMLS CUI-2)
Patient ID (derived)
Item
Patient ID (derived)
text
C2348585 (UMLS CUI [1])
Visit
Item
Visit Info
text
C0545082 (UMLS CUI [1])
Multiple sclerosis relapse
Item
Recent relapse of MS
boolean
C0856120 (UMLS CUI [1,1])
Vaccination
Item
Recent vaccination ≤ 6 weeks
boolean
C0042196 (UMLS CUI [1])
Malignancy
Item
Malignancy, except basal skin cell carcinoma
boolean
C0006826 (UMLS CUI [1])
bleeding disorder
Item
Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)
boolean
C3251812 (UMLS CUI [1])
Pregnant or lactating
Item
Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
Major systemic disease
Item
Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety
boolean
C0442893 (UMLS CUI [1])
Low platelet count
Item
Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP
boolean
C0040034 (UMLS CUI [1])
Low CD4, CD8 or CD 19
Item
CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed
boolean
Low Neutrophil cell count
Item
Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed
boolean
C0853697 (UMLS CUI [1])
Other illness
Item
Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab
boolean
C3843746 (UMLS CUI [1])
Item
Treatment with immunosuppressive or antineoplastic drugs
text
C0021081 (UMLS CUI [1])
Criteria for Treatment Deferral: No 11 yes/no
Code List
Treatment with immunosuppressive or antineoplastic drugs
CL Item
yes (1)
CL Item
no (0)
No Criteria for Treatment Deferral
Item
Is the patient free of the above listed deferral criteria?
boolean
C0205421 (UMLS CUI [1])
Comment Treatment deferral
Item
Comment Treatment deferral
text
C0205421 (UMLS CUI [1,1])
C0947611 (UMLS CUI [1,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial